TridAnt includes active and passive components. The result, according to BioInteractions, is a non-leaching coating that provides infection resistance to a surface and reduces biofilm formation — all without any toxic or eluting components. The coating targets a broad spectrum of bacteria, which significantly reduces the risk of infections.
“Our TridAnt solution offers a new way to combat infections more effectively, efficiently and for longer,” said Arjun Luthra, commercial director for BioInteractions.
“Based on over three decades of dedicated research and trials, TridAnt is fully compliant with current medical device regulations, has been independently tested to international standards (ISO, EN, PAS) and proven to provide monoclonal protection which kills a broad spectrum of gram-positive & gram-negative bacteria as well as enveloped & non-enveloped viruses, including E.coli, MRSA, influenza, norovirus and SARS-Cov-2. TridAnt is suitable for skin protection as well as most other surfaces including woven and non-woven fabrics including metals (Nitinol) as well as polymers (polycarbonate & polyurethanes).”
BioInteractions is marketing TridAnt for use on venous and urinal catheters, contact lenses, titanium cranioplasty, and wound dressings — as well as labels and protective paint for ships.